dual FPR1/FPR2 agonist (Baker IDI/Limulus Therapeutics)

N/A

Report date: 2025/03/19 09:03:29
NME

Base Information

Drug Namedual FPR1/FPR2 agonist (Baker IDI/Limulus Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionN-formyl peptide receptor 2 agonists
TargetsN-formyl peptide receptor 2
Therapy Area/IndicationsMyocardial Reperfusion Injury
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBaker Idi Heart And Diabetes Institute Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLimulus Therapeutics Pty LtdBaker Idi Heart And Diabetes Institute Holdings Ltd
Inactive CompaniesN/A
Active IndicationsMyocardial Reperfusion Injury
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A